Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (April 2012)

22 slides from Paratek Pharmaceuticals's investor presentation, Apr 3, 2012

  1. Slide 1: Specialty pharmaceutical company focused on neuroscience

    Exhibit 99.1 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience April 2012

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectat

  3. Slide 3: Transcept: preparing for Intermezzo commercialization

    Transcept: preparing for Intermezzo ® commercialization Therapeutic focus Neuroscience / psychiatry Large markets, Intermezzo: middle of the night awakenings unmet needs TO-2061: treatment resistant OCD Commercial U.S. primary care partnership: Purdue Pharma platform Option to co-promote Intermezzo

  4. Slide 4: Intermezzo (zolpidem tartrate) sublingual tablet

    Intermezzo® (zolpidem tartrate) sublingual tablet C-IV 4

  5. Slide 5: Intermezzo: first and only sleep aid approved for middle-of-the-night dosing

    Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing Indication statement as approved by FDA: – Intermezzo is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. – Interm

  6. Slide 6: Intermezzo: first and only prescription sleep aid approved for middle-of-the-night dosing

    Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing 6

  7. Slide 7: Middle of the night awakening: a major unmet medical need in insomnia

    Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Large U.S. insomnia market – 79 million new and refill prescriptions (1) Insomnia is an under-treated condition(2) – 11 million patients receive Rx (3) – 4x to 6x more are not diagnosed or treated by a physicia

  8. Slide 8: Commonly prescribed sleep aids are indicated only for bedtime use

    Commonly prescribed sleep aids are indicated only for bedtime use MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien ®, Ambien CR ®, Lunesta®) require bedtime prophylactic dosing to prevent awakenings An ideal therapeutic would: – Be used only at the time patients need help

  9. Slide 9: Intermezzo: first and only sleep aid approved for middle-of-the-night dosing

    Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Novel zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers Approved dose – 1.75 mg in women & patients > 65 years – 3.5 mg in non-elderly men Rapidly absorbed in both men and women Effective vs. plac

  10. Slide 10: Intermezzo: National product launch early April 2012

    Intermezzo: National product launch early April 2012 10

  11. Slide 11: Significant Rx insomnia market opportunity: each 1% share $150M

    Significant Rx insomnia market opportunity: each 1% share $150M at gross price (WAC) 2 U.S. insomnia market 79 million TRx per year 1 Intermezzo pricing $6.45 per tablet gross price (WAC) 2 30 tablets per Rx 3 Average Rx value: ~$190 Hypothetical market 1% Intermezzo share penetration 790,000 TRx ap

  12. Slide 12: Intermezzo launch plans

    Intermezzo launch plans Promotion to begin early April 2012 Purdue plans to invest ~$100M during first 12 months of Intermezzo launch ~275 field representatives in new national sales force devoted exclusively to the promotion of Intermezzo to highest insomnia prescribers Purdue began contacting drug

  13. Slide 13: Purdue commercialization agreement: key Transcept benefits

    Purdue commercialization agreement: key Transcept benefits Co-promote option: foundation for a commercial future – Transcept can begin promotion to psychiatrists between 8 and 15 months after exercise of option depending on when in the calendar the exercise is made Royalty structure – Base royalty:

  14. Slide 14: Intermezzo: intellectual property

    Intermezzo: intellectual property

  15. Slide 15: Two U.S. patents issued, additional patent applications pending

    Two U.S. patents issued, additional patent applications pending Two issued U.S. patents - 7,682,628 and 7,658,945 – Buffered formulations – Compositions and methods of treating insomnia – Claims require absorption of zolpidem across the oral mucosa – Patents expire no sooner than February 2025 Paten

  16. Slide 16: TO-2061: proposed indication in OCD

    TO-2061 Proposed indication: adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication 16

  17. Slide 17: Significant unmet medical need: OCD patients not responding adequately

    Significant unmet medical need: OCD patients not responding adequately to approved medication Obsessive Compulsive Disorder – Intrusive thoughts and repetitive actions to reduce distress – Affects 1% to 2% of U.S. adult population, 40% to 50% seek treatment – Significantly impacts everyday life acti

  18. Slide 18: Pilot Study B: improvement measured as % decrease below baseline

    Pilot Study B: Improvement measured as % decrease below baseline Pilot Study B, n=21 0% 0% 10% 10% 20% 20% 30% 30% 40% 40% Responders (57% of patients) All patients Non-responders (43% of patients) 50% 50% Week Week Week Week Week Week Week Week Week Week Week Week 2 4 6 8 10 12 2 4 6 8 10 12 All Pa

  19. Slide 19: TO-2061: 505b2 NDA pathway

    TO-2061 505b2 NDA pathway Phase 2 double blind, placebo controlled study, n 150, complete enrollment est. Fall 2012, top line data est. Q1 2013 Intellectual property – Method of use patent application filed, priority date May 19, 2009 – Ondansetron, up to ~1.5 mg/day – Pending claims for treating SS

  20. Slide 20: Financial overview

    Financial overview Transcept HARMACEUTICALS, INC.

  21. Slide 21: Financial position

    Financial position 12/31/2011 Cash & investments: $62.4 M 2/1/2012 update Shares outstanding: 13.9 M Options / warrants / other: 3.6 Total: 17.5 M Employees: 18 21

  22. Slide 22: Trademark notices

    Intermezzo ® is a registered trademark of Transcept Pharmaceuticals, Inc. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc. Zofran ® and Paxil ® are registered trademarks of The GlaxoSmithKline Group of Companies

Transcept Pharmaceuticals — Investor Presentation (April 2012) on 6ix